Truist Financial Sticks to Their Buy Rating for Exelixis (EXEL)
Truist Financial analyst Asthika Goonewardene reiterated a Buy rating on Exelixis today and set a price target of $51.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Goonewardene is an analyst with an average return of -3.3% and a 38.73% success rate. Goonewardene covers the Healthcare sector, focusing on stocks such as Genmab, Exelixis, and Revolution Medicines.
In addition to Truist Financial, Exelixis also received a Buy from William Blair’s Andy Hsieh in a report issued on January 12. However, on the same day, Barclays maintained a Hold rating on Exelixis (NASDAQ: EXEL).
Based on Exelixis’ latest earnings release for the quarter ending October 3, the company reported a quarterly revenue of $597.76 million and a net profit of $193.58 million. In comparison, last year the company earned a revenue of $539.54 million and had a net profit of $117.97 million
Based on the recent corporate insider activity of 88 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EXEL in relation to earlier this year. Most recently, in November 2025, DAVID EDWARD JOHNSON, a Director at EXEL bought 27,532.00 shares for a total of $1,187,179.84.
Read More on EXEL:
Disclaimer & DisclosureReport an Issue
- Exelixis reports preliminary FY25 revenue $2.32B, consensus $2.33B
- Exelixis sees FY26 revenue $2.525B-$2.625B, consensus $2.62B
- Exelixis price target raised to $52 from $49 at H.C. Wainwright
- Exelixis downgraded to Equal Weight from Overweight at Morgan Stanley
- Exelixis, Natera announce collaboration on STELLAR-316 trial
